

Index

Note: The page numbers with letter 'f' denote figures and page numbers with letter 't' denote tables.

A

- Å6, 92–93
- A431 (cell line), 190, 213
- AACOFC₃, 250, 273
- 17-AAG, *see* 17-Allylaminogeldanamycin (17-AAG)
- ABC2, 135
- Aberrant epithelial differentiation, 147–160
 - cancer stem cell concept and, 158–160
 - GATA transcription factors in, 148–151
 - loss of GATA6 function and, 151–153
 - mechanism for loss of GATA factors, 154–156

See also Epithelial dedifferentiation
- ABT869, 98
- ABT888, 78
- ABX-EGF, 68
- Acetaminophen, 19
- Acidic fibroblast growth factor (aFGF), 310–311
- Acid phosphatase (ACPT), 167
- Actinin-4, 308, 328
- Activator protein 1 (AP-1), 6, 8–9, 19, 156, 277
- Actomyosin, 289
- Acute lymphoblastic leukemia, 170, 307
- ADAM-17, 283
- ADAM, 211
- Adeonvirus expressing Cre-recombinase (Ad-Cre), 370, 371, 373, 374
- Adhesion molecule regulation, 284
- AEE788, 68t
- AG014699, 78
- AHRI, 96t
- AJCC TNM staging system, 36
- Akt1, 364, 365, 366
- Akt, 88, 91, 116, 232
 - in animal models, 364, 368, 372, 374
 - chemoprevention and, 6, 7
 - E-cadherin and, 325
 - mTOR and, 72
 - phytochemicals and, 21
 - retinoids and, 19
 - SPARC and, 115
- Alendronate, 291
- 17-Allylaminogeldanamycin (17-AAG), 73
- Amphiregulin, 203, 206
- Anabolism, 255–256
- Androgen receptor (AR), 173
- Androgens, 4, 111
- Angiogenesis, 64, 87, 308–311
 - lysophosphatidic acid and, 276–277
 - mitogens and motogens, 310–311
 - selectins and, 305
- Angiogenic switch, 369
- Angiogenin, 87
- Angiopoietin family of growth factors, 310
- Angiostatin, 65
- 4-Anilinoquinazoline, 209
- Animal models, 353–380
 - chemically induced, 358
 - chemoprevention studies, 23–25
 - of *ex vivo* epithelial transformation, 358–360
 - genetically engineered, 353, 366–376
 - genetically induced transformation in, 362–366
 - spontaneous, 354–355
 - spontaneous immortalization and transformation in, 360–362
 - viral immortalization and transformation in, 359–360

- Anoikis, 325, 330
 Antioxidant response element (ARE), 20
 AP-1, *see* Activator protein 1 (AP-1)
 AP23573, 72
 Apaf-1, 135
 Apc, 373–374
 Apoptosis, 173
 phytochemicals and, 21
 progestins and, 4–5, 11, 12, 355
 retinoids and, 19, 20
 role in prevention, 9
 vitamin D and, 14, 17, 18
 APPL1, 234
 APPL2, 234
 Arf, 229
 Argon beam coagulator (ABC), 37, 38
 ARHI, 110t, 112–113, 121–122, 135
 ARLTS1, 111t, 118, 122
 ARRY-142886, 74
 Ascites, ovarian cancer
 3D metastasis models of, 344, 345
 hypoxia and autotaxin activity in, 245
 invasion and, 269, 273
 microenvironment of, 322–324
 ATBC Cancer Prevention Study, 6
 Autotaxin/lysophospholipase D (ATX/
 LysoPLD), 243–247, 249, 252, 253,
 260, 273–275, 277
 activity in ovarian cancer, 243
 cellular sources of, 243–244
 expression of, 244
 regulation of, 244–247
 AVE0005, 66
 AVE8062, 378
 5-Azacytidine, *see* Vidaza
 5-Azadeoxycytidine (Decitabine), 118, 138, 155
 AZD6244, 74
- B**
 Bad (transcription factor), 7
 BAP-1, 136
 Basic fibroblast growth factor (bFGF), 87,
 245, 310
 Batimastat, 73
 Bax, 121
 BAY 43–9006, *see* Sorafenib
 BB-2516, 73
 Bcl-1, 87
 Bcl-2, 8, 134, 347
 Bcl-XL, 8
 Bcr-Abl, 64, 70
 Belinostat, 139
 Betacellulin, 203
 Bevacizumab, 65, 71, 86, 88, 89, 90t, 307,
 309–310
 BIBF 1120, 91
 Bilateral pelvic lymphadenectomy, 36, 40, 47
 Bilateral salpingo-oophorectomy (BSO), 36,
 43, 47
 Bioluminescent imaging (BLI), 378–379
 Biomarkers
 DNA methylation, 136–137
 kallikreins as, 170
 soluble EGFR as, 189–198
 Biomarker targets, 85–99
 as prognostic factors, 94–98
 rationale for, 86–88
 recurrent disease and, 88–93
 Biopsy, 36
 Bisphosphonates, 235
 Black raspberries, 7
 Bladder cancer, 138, 231, 233, 235
 Bortezomib, 73–74, 89, 92
 Bradykinin, 165
 Bradykinin B2 receptor, 168
 BRAF, 231, 347, 364
 Brain cancer, 370
 BRCA1, 77–78, 85, 87, 109, 122, 136, 137,
 191–192
 in animal models, 366, 374–376
 location and function of, 111t, 120–121
 BRCA2, 77–78, 87, 109, 111t, 117–118, 122
 Breast cancer, 74, 86, 120, 140, 191, 233,
 233, 236
 3D models of, 342
 animal models of, *see* Mammary gland
 cancer
 autotaxin and, 245, 275
 cyclin-dependent kinase inhibitors
 and, 76
 kallikreins and, 170
 lysophosphatidic acid and, 253
 omega-3 fatty acids and, 22
 selectins and, 303
 Brm, 136
 Bromomethylene (BEL), 250
 Butyrolactone I, 76
- C**
 2C4, *see* Pertuzumab
 C225, *see* Cetuximab
 CA-125, 93, 94, 98, 193, 304, 364
 kallikreins and, 175
 soluble EGFR and, 196–197

- Cadherins, 298–302, 321
 in cancer, 300–301
 epithelial (E), *see* E-cadherin
 intraperitoneal survival and, 324–325
 neural (N), *see* N-cadherin
 in ovarian cancer, 302
 pathway, 298–302
 placental (P), 298
 signaling, 299
 vascular endothelial (VE), 298
- Caffeic acid phenethyl ester, 9
- Calcitriol, 14–15
- Calcium-independent phospholipase
 A_2 (iPLA₂), 247, 249–252, 253, 260,
 272, 273, 274
- California Teachers Study, 21
- Cancer stem cells, 158–160
- Cancer and Steroid Hormone Study
 (CASH), 13
- Canertinib, *see* CI-1033
- Caov-3 (cell line), 255, 277, 284, 291
- Carboplatin, 89, 92, 137, 140, 194, 197, 378
 belinostat and, 139
 bortezomib and, 73–74
- Carcinogenesis, chemoprevention and, 5–6
- CARMA3, 279–280
- 3-Carotene, 20
- Caspase-3, 251, 347
- Caspase-9, 7
- Catenin, 299, 300, 336, 347, 373, 374
- Cathepsin D, 94, 379
- Catumaxomab, 89
- Caveolin-1, 213
- CCI-779, *see* Temsirolimus
- CD44, 327, 337, 340, 377
- Cdc42, 232
- CDH1, 301
- CDKN1, 135
- Cell adhesion, 297–311, 321–322, 336–337
See also Cell-cell adhesion; Cell-matrix
 adhesion
- Cell-cell adhesion, 297–305, 336
 angiogenesis and, 305, 308–311
 cadherins and, 298–302, 321
 metastasis and, 321–322, 325
 selectins and, 302–305
- Cell cycle regulators, inhibitors of, 76–77
- Cell-matrix adhesion, 320, 327
 angiogenesis and, 308–311
 characteristics of, 305–308
- Cervical cancer, 67, 190
- Cetuximab, 67, 68t, 70, 89, 90t
- C-fms, 87, 96t, 98
- Chemoprevention, 3–25
 agents used in, 10–23
 animal models in, 23–25
 carcinogenesis and, 5–6
 combinatorial, 22–23
 defined, 5
 molecular targets for, 6–9
 ovarian epithelium as target for, 4–5
- Chemotherapy
 cytoreduction and, 50, 51–53
 EGFR and, 209–210
 hyperthermic intraperitoneal, 55
 neoadjuvant, 49–51
See also specific agents
- Chickens, 4, 24–25, 190, 354, 359
- Cholangiohepatoma, 235
- Cholecalciferol, 15–16
- Choroideremia, 234
- C-H-Ras, 365
- Chromatin, 154–155, 160
- Chromosome 1, 112–113
- Chromosome 3, 113–114
- Chromosome 4, 165
- Chromosome 5, 114–115
- Chromosome 6, 115–116
- Chromosome 10, 116–117
- Chromosome 11, 119
- Chromosome 13, 117–118
- Chromosome 16, 118
- Chromosome 17, 118–121
- Chromosome 19, 121, 165
- Chronic myelogenous leukemia, 307
- Chronic myeloid leukemia (CML), 64, 70
- CI-1033, 70, 89, 91
- CI-1040, 74
- Cisplatin, 73, 86, 139–140, 209, 269, 368, 377
- C-kit, 66, 70–71, 86, 89, 90t, 98
- Clathrin, 156
- Claudin-4, 135
- Clear cell ovarian cancer, 255, 259, 319, 353
- Clinical presentation of ovarian cancer,
 193–196
- Clostridium botulinum* C3, 287
- C-myc, 89, 232, 299, 364, 365, 366
- COL21A1, 122
- Collagen I, 323, 328, 328, 337–338, 342, 343,
 344, 342, 344
- Collagen III, 323, 327
- Collagen IV, 151, 152, 156, 157, 337, 340
- Colon/colorectal cancer, 66, 74, 191, 233,
 304, 306
 cyclin-dependent kinase inhibitors
 and, 76

- Colon/colorectal cancer (*cont.*)
 EGFR and, 209
 kallikreins and, 170
 lysophosphatidic acid and, 253, 254
 MMP-7 and, 281–282
 omega-3 fatty acids and, 22
 Colony-stimulating factor-1 (CSF-1), 98, 324
 Computed tomography (CT), 376
 Conditional genetic models, 369–376
 Connective tissue growth factor (CTGF),
 328–329
 Connexin-43, 362
 Corpus uteri cancer, 191
 COSMIC project, 232
 COX-1, 22, 368
 COX-2, 8, 9, 21, 116, 276, 281, 283–284
 CpG islands, 131, 135, 136, 154–155
 cPLA₂, *see* Cytosolic phospholipase
 A₂ (cPLA₂)
 c-RAF1, 235
 Cre-recombinase, *see* Adenovirus expressing
 Cre-recombinase (Ad-Cre)
 CRM197, 209
 CSF, *see* Colony-stimulating factor-1
 (CSF-1)
 C-src, 211
 CTGF, *see* Connective tissue growth factor-
 1 (CSF-1)
 Curcumin, 7, 8, 9
 Cutaneous T-cell lymphoma, 139
 CY1503, 305
 Cyclin D, 8, 76
 Cyclin D1, 113, 114, 120, 299
 Cyclin-dependent kinase inhibitors (CKIs),
 76–77
 Cyclophosphamide, 66, 194, 197
 CYT645, 98
 Cytooreduction, 44–55
 clinical benefits supporting, 45–48
 interval, with chemotherapy, 49–51
 predicting optimal, 54–55
 for recurrent ovarian cancer, 51–54
 theoretical benefits supporting, 44
 Cytosolic phospholipase A₂ (cPLA₂), 247,
 248–249, 252, 260, 272, 273, 274
- D**
 Dab-2/DOC-2, 96t, 122
 aberrant epithelial differentiation and,
 151, 152, 153, 156–157
 location and function of, 110t, 115
 Daidzein, 21
 DAPK, 135
 Dasatinib, 307
 3-Deazaadenosine (DZNep), 140
 Decitabine, *see* 5-Azadeoxycytidine
 (Decitabine)
 DESKTOP OVAR trial, 54
 Diethylstilbestrol, 358
 Differential diagnosis, 196–197
 Diosgenin, 7
 DIRAS3, *see* ARHI
 Disease-free survival (DES), 181
 DLC-3, 233
 DLEC1, 110t, 114, 122
 17-DMAG, 73
 DMBA, 358
 DNA methylation, 131–133, 134, 135
 biomarkers for screening/prognosis,
 136–137
 inhibitors of, 137–138
 DNA methyltransferase (DNMT), 131,
 132f, 136
 DOC-2, *see* Dab-2/DOC-2
 Dov13 (cell line), 243, 250, 257, 276, 277, 280,
 281–282
- E**
 E1A, 91
 E2F1, 112
 E2F4, 112
 E-cadherin, 87, 362, 363
 cell-cell adhesion and, 298, 299, 301, 302,
 322, 325
 EGFR and, 210, 214, 214
 lysophosphatidic acid and, 280, 284
 melanoma and, 341
 metastasis and, 321, 324, 327
 MMP-7 and, 281–282
 MMP-9 and, 327
 ECM, *see* Extracellular matrix (ECM)
 ECO-4601, 92
 Ecto-nucleotide phosphodiesterase (ENPP),
 244, 274
 EDTA, *see* Ethylenediamine tetraacetic acid
 (EDTA)
 EEAI1, 234
 EGCG, *see* Epigallocatechin-3-gallate
 (EGCG)
 EGFR, *see* Epidermal growth factor
 receptor (EGFR)
 EGF, *see* Epidermal growth factor (EGF)
 Egr-1, 327
 EGTA, 247

- EKB-569, 68t, 69
 EMD72000, *see* Matuzumab
 EMT, *see* Epithelial-mesenchymal transition (EMT)
 Endometrioid ovarian cancer, 254, 319, 353, 358, 372–373
 Endostatin, 65
 Endothelin-1 (ET-1), 211–212
 Enhancer of Zeste-2 (EZH2), 132f, 133, 140
 ENPP, *see* Ectonucleotide phosphodiesterase (ENPP)
 Enzastaurin, 89
 EpHA2, 95t, 98
 Epidemiology of ovarian cancer, 191
 Epidermal growth factor (EGF), 206, 245
 Epidermal growth factor receptor (EGFR), 203–217, 234
 activation of, 208–210
 background, 203–205
 chemoprevention and, 6, 7
 consequences of sustained activation, 213–216
 expression of, 205–206
 expression of and clinical correlates, 206–208
 isoforms of, 189–191
 ligands interacting with, 203–205, 211–212
 in the microenvironment, 210–213
 pathogenesis and, 192–193
 phospho-, 207–208, 216
 soluble, *see* Soluble epidermal growth factor receptor (sEGFR)
 as a therapeutic target, 67–71, 88–91
 Epidermal growth factor receptor variant III (EGFRvIII), 207, 214
 Epigallocatechin-3-gallate (EGCG), 7, 9, 138
 Epigen, 203
 Epigenetics, 131–141
 aberrations in ovarian cancer, 134–136
 defined, 131
 management of ovarian cancer, 136–140
 Epiregulin, 203
 Epithelial cell adhesion molecule (EpCAM), 89
 Epithelial dedifferentiation, 147, 156–158, 160
 Epithelial differentiation, aberrant, *see* Aberrant epithelial differentiation
 Epithelial-mesenchymal transition (EMT), 205, 210, 212, 213, 216, 325, 330
 Epstein-Barr virus, 245
 ErbB-1, 67, 89, 189, 203
 ErbB-2, 67–68, 89, 91, 189, 203, 363
 See also HER-2 (neu)
 ErbB-3, 67, 91, 189, 203, 204
 ErbB-4, 67, 91, 189, 203, 204
 ErbB (family), 67–70, 189, 203
 ERK, *see* Extracellular signal-regulated kinase (ERK)
 Erlotinib, 68t, 69, 70, 88, 89, 90t
 ES2 (cell line), 152
 E-selectin, 303, 304, 305
 Esophageal cancer, 281
 Estrogen, 4, 11, 355, 358
 Estrone, 111
 Ethinyl estradiol, 10–13
 Ethylenediamine tetraacetic acid (EDTA), 245, 247
 Etiology of ovarian cancer, 191–192
 ET, *see* Endothelin-1 (ET-1)
 European Organization for Research and Treatment of Cancer (EORTC), 50
 Everolimus (RAD001), 72, 368, 377
 Extracellular matrix (ECM)
 3D metastasis models and, 341–342, 343, 344–345, 346
 cell adhesion and, 305–306, 307, 308
 lysophosphatidic acid and, 271
 Extracellular signal-regulated kinase (ERK), 115, 274, 290
 G_{i/o}, 288
 Extraembryonic endoderm lineages, 148–151
Ex vivo transformation, 358–359
 EZH2, *see* Enhancer of Zeste-2 (EZH2)
- F**
 FAK, *see* Focal adhesion kinase (FAK)
 Farnesyltransferase (FTase), 71, 231
 Farnesyltransferase inhibitors (FTIs), 71, 235, 236, 279–280
 FDG, *see* [¹⁸F] Fluorodeoxyglucose (FDG) positron emission tomography (PET)
 Fenretinide, 19
 Fenugreek, 7
 Fertility preservation, 40–44
 Fibroblast growth factor (FGF), 91, 310–311
 Fibroblasts, in metastasis, 339, 343, 344, 345–346
 Fibronectin, 168, 308, 337, 340, 345
 FIGO staging system, *see* International Federation of Gynecology and Obstetrics (FIGO) staging system
 Flavopiridols, 76

- FLT, *see* [¹⁸F] Fluorothymidine (FLT) positron emission tomography (PET)
- FLT-s, 66
- Fluorescent imaging (FLI), 378–379
- [¹⁸F] Fluorodeoxyglucose (FDG) positron emission tomography (PET), 377–378
- [¹⁸F] Fluorothymidine (FLT) positron emission tomography (PET), 377–378
- Focal adhesion kinase (FAK), 290, 291, 307, 362
- FOG (friend of GATA), 154
- Follicle-stimulating hormone- β subunit knockout (FSHbKO) mice, 369
- Follicle-stimulating hormone (FSH), 111, 195
- Follicle-stimulating hormone receptor (FSHR), 369, 374
- Follitropin receptor knockout (FORKO) mice, 369
- Forkhead transcription factor, 7
- Foxo1, 362
- FTase, *see* Farnesyltransferase (FTase)
- G**
- Gastrointestinal cancer, 73, 76, 303
- Gastrointestinal stromal tumors (GISTs), 64, 86
- GATA1 transcription factor, 150
- GATA2 transcription factor, 150
- GATA3 transcription factor, 150, 153
- GATA4 transcription factor, 135, 150, 151, 153, 155, 157
- GATA5 transcription factor, 150, 153, 155
- GATA6 transcription factor, 135, 148–156, 159, 160
- inactivation of, 156–157
- loss of function, 151–153
- mechanism for loss of, 154–156
- GDI, *see* Guanine nucleotide dissociation inhibitors (GDIs)
- Gefitinib, 68t, 69, 70, 89, 90t, 212
- Geldanamycin, 73
- Gemcitabine, 71
- Genetically engineered mouse (GEM) models, 353, 366–376, 380
- Genistein, 7, 21
- Geranylgeraniol (GGOH), 291
- Geranylgeranylacetone (GGA), 291
- Geranylgeranyltransferase, 231, 235, 236
- Geranylgeranyltransferase inhibitors (GGTIs), 235
- Germ-line deletions, 369
- GGA, *see* Geranylgeranylacetone (GGA)
- GGOH, *see* Geranylgeraniol (GGOH)
- Gleevec, *see* Imatinib
- Gliomas, 153, 253, 275
- Glucose-regulated protein 78 (GRP78), 94
- Glyburide, 253
- Glycitein, 21
- GM6001, 340
- GOG, *see* Gynecologic Oncology Group (GOG)
- GOG239, 74
- Goldie-Coldman hypothesis, 3
- Gompertzian cell growth curve, 44
- Gonadotropin-releasing hormone analogues, 275
- GPCR, *see* G-protein-coupled receptor (GPCR)
- GPI21016, 78
- GPR23, 254
- GPR92, 254, 286
- G-protein-coupled receptor (GPCR), 211, 216, 269, 285–287
- Grb2, 67, 115
- Green tea, 7, 8
- Griscelli syndrome type 2 (GS2), 234
- GRO- α , 253
- GRP, *see* Glucose-regulated protein 78 (GRP78)
- Guanine nucleotide dissociation inhibitors (GDIs), 231, 234
- GW572016, *see* Lapatinib
- Gynecologic Oncology Group (GOG), 14, 85–86
- bevacizumab evaluated by, 66
- gefitinib evaluated by, 69
- GOG239 activation and, 74
- surgery analysis by, 45–49, 50, 54, 55
- H**
- Halidomide, 66
- Haloenol lactone suicide substrate (HELSS), 250, 273
- HB-EGF, *see* Heparin-binding EGF-like growth factor (HB-EGF)
- HDM2, 119
- Head and neck cancer, 208, 209, 233, 281
- Heat shock protein 90 (Hsp90), 73–74

- HELSS, *see* Haloenol lactone suicide substrate (HELSS)
- Hemophagocytic syndrome, 234
- Heparin-binding EGF-like growth factor (HB-EGF), 203, 206, 209, 211–212, 216
- Hepatocellular carcinoma, 74, 235
- HER-2 (neu), 6, 25, 67–69, 87, 88, 189, 366
chemoprevention and, 7
as a therapeutic target, 89–91, 95t
See also ErbB-2
- HER-3, 189, *see also* ErbB-3
- HER-4, 189, *see also* ErbB-4
- Hermansky-Pudlak syndrome, 234
- HEY (cell line), 243, 249, 253, 272, 282, 283, 284
- HIF-1 α , 277, 285
- High-grade (type II) malignancies, 319–320, 347
- HIO (cell line), 152
- Histidine, 245
- Histone acetylation, 133, 154
- Histone acetyltransferase (HAT), 133, 154
- Histone code hypothesis, 133
- Histone deacetylase (HDAC), 132f, 133, 154
- Histone deacetylase inhibitors (HDACIs), 138–139
- Histone deacetylation, 133, 135, 136, 155
- Histone methyltransferase (HMT), 154
- Histone modification, 131, 134, 135, 155–156, 160
- History of ovarian cancer, 193
- HKI-272, 68t, 69, 70, 89–91
- hMLH1, 137
- HNPCC, 109
- Hodgkin lymphoma, 245
- Homologous recombination (HR), 121
- HOSE (cell line), 257–258, 271, 360, 362–363
- HOXA11, 137
- HP1, 154, 155
- 4-HPR, *see* 4-(*N*-Hydroxyphenyl)retanimide (4-HPR)
- HPV 16, *see* Human papilloma virus 16 (HPV 16)
- H-ras, 25, 229, 231, 232, 235, 290, 364
- Hsp, *see* Heat shock protein 90 (Hsp90)
- Hsulf-1, 135
- hTERT, *see* Human telomerase reverse transcriptase (hTERT)
- Human adenovirus type 5, 91
- Human cells
genetically induced transformation in, 362
viral immortalization and transformation in, 359
- Human Epigenome Project, 131
- Human Genome Project, 131, 171
- Human papilloma virus 16 (HPV 16), 360
- Human telomerase reverse transcriptase (hTERT), 363, 364
- Hyaluronan, 340
- Hydralazine, 138, 140
- Hydrocortisone, 210
- 9-Hydroxyellipticine, 76
- Hyperthermic intraperitoneal chemotherapy (HIPEC), 55
- Hypoxia, 245–246, 276–277, 284–285
- I**
- ICAM-1, 135
- Id1, 135
- IGF-1, *see* Insulin-like growth factor-1 (IGF-1)
- IGFBP-3, *see* Insulin-like growth factor-binding protein-3 (IGFBP-3)
- IL (Interleukin), 8, 92, 113, 245, 253, 257, 276, 277, 282, 324, 364
see also specific Interleukin
- Imaging, *in vivo*, 376–379
- Imatinib, 64, 86, 89, 90t
- Immunotherapy, 93–94
- Incessant ovulation hypothesis, 4, 358–359
- Incidence of ovarian cancer, 191
- Indole 3-carbinol, 7
- Initiation, 5
- INK4, 76
- INO-1001, 78
- Insulin-like growth factor-1 (IGF-1), 113, 362–363
- Insulin-like growth factor-1 receptor (IGF-1R), 363
- Insulin-like growth factor-binding protein-3 (IGFBP-3), 168, 172
- Integrin α 2, 214, 322, 341
- Integrin α 2 β 1, 327, 337
- Integrin α 3, 322
- Integrin α 3 β 1, 327
- Integrin α 5, 322, 345–346
- Integrin α 5 β 1, 235, 308
- Integrin α 5 β 3, 308
- Integrin α 6 β 4, 245, 322
- Integrin α 6 β 1, 345
- Integrin α v, 308, 322

- Integrin $\alpha\beta_3$, 345
 Integrin β_1 , 281, 308, 322, 327, 340
 Integrin β_3 , 322
 Integrin (s), 306–308, 321–322, 336
 matrix interactions with, 322, 327–329
 melanoma and, 341
 signaling, 306–307
 Interleukin-1 β (IL-1 β), 245, 364
 Interleukin-4 (IL-4), 245
 Interleukin-6 (IL-6), 92, 253, 257, 277,
 324, 364
 Interleukin-8 (IL-8), 8, 113, 253, 257, 276,
 277, 282, 364
 Interleukin-10 (IL-10), 328
 Interleukin-12 (IL-12), 328
 International Federation of Gynecology and
 Obstetrics (FIGO) staging system,
 35–368, 39, 41–43t, 48t
 Intestinal cancer, 253
 Intraoperative heated chemotherapy, 55
 Invasion
 integrin activation of phenotype,
 307–308
 lysophosphatidic acid and, *see*
 under Lysophosphatidic acid
 (LPA)
In vitro models of ovarian cancer, 270–271,
 339–341
In vivo imaging, 376–379
In vivo models of ovarian cancer,
 270–271
 See also Animal models
 IOSE 29 (cell line), 278, 286
 IOSE 80 (cell line), 278
 iPLA₂, *see* Calcium-independent
 phospholipase A₂ (iPLA₂)
 ISIS2503, 235
 ISIS5132, 235
 Isoflavones, 21, 22
 Isothiocyanates, 21–22
- K**
- Kallikreins, 165–182
 clinical utility of, 173–181
 as diagnostic markers, 173–175
 differential expression of, 171
 expression in cancer, 170–173
 gene and protein names, 166t
 mechanisms of involvement, 172–173
 in normal physiology, 168–169
 prognostic applications, 175–181
 regulation of, 169–170
 splice variants, 171–172
 structure and genomic organization,
 165–167
 subcellular localization of, 171
 therapeutic applications, 181
 tissue expression and hormonal
 regulation, 167–168
 Keratin 5 (K5), 364, 366
 Ki20227, 98
 Ki-67, 87
 Kidney cancer, 233
 Ki-MSV, 359
 Kinins, 172–173
 Ki-Ras, 358
 KLK1, 165, 166t, 168, 169, 173
 KLK2, 166t, 167, 169, 170, 172
 KLK3, 166t, 167, 169, 170, 172, 173, 181
 KLK4, 166t, 168–169, 171, 172, 176t, 181
 KLK5, 166t, 167, 169, 170, 172, 176t
 KLK6, 166t, 167, 168, 169, 170, 171, 172,
 173, 175, 177t, 182
 KLK7, 166t, 167, 168, 169, 170, 172,
 177t, 181
 KLK8, 166t, 167, 168, 169, 170, 171,
 178t, 181
 KLK9, 166t, 168, 170, 171, 178t, 181
 KLK10, 166t, 168, 169, 170, 171, 173, 175,
 179t, 181, 182
 KLK11, 166t, 168, 169, 170, 172, 179t, 181
 KLK12, 166t, 168
 KLK13, 166t, 167–168, 170, 180t, 181
 KLK14, 166t, 168, 170, 171, 180t, 181
 KLK15, 166t, 168, 169, 170, 180t, 181
 K-ras, 71, 289, 364, 365
 in animal models, 364, 365, 366,
 371–373
 type 1 cancers and, 347
 KU-00559436 (KuDOS), 77–78
- L**
- Lactation, 192
 Laminin, 151, 152, 153, 156–157, 337
 Laparoscopy, 38t–39t
 Laparotomy, 38t–39t
 Lapatinib, 68t, 69, 89
 Lecithin-cholesterol acyltransferase
 (LCAT), 252
 Let-7, 134
 Leukemia
 acute lymphoblastic, 170, 307
 chronic myelogenous, 307
 chronic myeloid, 64, 70

Ligands

- interacting with EGFR, 203–206, 211–212
- selectin, 303–304
- Lipid-degrading enzymes, 255–255
- Lipid generation and signaling, 241–260
 - See also Lysophosphatidic acid (LPA)
- Lipid phosphate phosphatase (LPP), 254–255, 275
- Liver cancer, 233, 235
- Loss of heterozygosity (LOH), 109, 112, 118, 119, 370, 371
- LOT-1, 96t, 110t, 112, 115, 122, 135
- Low-density lipoprotein (LDL) receptor family, 156
- Low-grade (type I) malignancies, 321–322, 349
- LoxP, 368, 372, 373, 374, 375, 376
- LPA, see Lysophosphatidic acid (LPA)
- LPAAT, see Lysophosphatidic acid acyltransferase (LPAAT)
- LPC, see Lysophosphatidylcholine (LPC)
- LPE, 292
- LPP, see Lipid phosphate phosphatase (LPP)
- L-selectin, 304
- LTR, 364
- Lung cancer, 67, 191, 233
 - animal models of, 369, 370
 - EGFR and, 208
 - kallikreins and, 170
 - MMP-7 and, 281
 - non-small cell, 70, 74, 76, 208
- Luteinizing hormone (LH), 111, 195
- LY294002, 280
- Lymphoma
 - cutaneous T-cell, 139
 - Hodgkin, 245
- Lysophosphatidic acid 1 (LPA₁) receptor, 253, 285–287
- Lysophosphatidic acid 2 (LPA₂) receptor, 253, 286–287
- Lysophosphatidic acid 3 (LPA₃) receptor, 253, 286–287
- Lysophosphatidic acid 4 (LPA₄) receptor, 254, 275, 286–287
- Lysophosphatidic acid 5 (LPA₅) receptor, 254
- Lysophosphatidic acid acyltransferase (LPAAT), 255–256
- Lysophosphatidic acid (LPA), 211, 212, 241–260, 323–324
 - elevated production of, 270
 - enzymes involved in anabolism, 255–256

- enzymes involved in generation, 242–254
- enzymes involved in reducing levels, 254–256
- epithelial-mesenchymal transition and, 325, 326f
- inactivation of, 275
- invasion and, 269–292
 - in vitro*, 270–271
 - in vivo*, 271–272
 - metabolic pathways in, 272–257
 - signal transduction pathways in, 287–290
 - small molecules inhibiting, 291
 - stimulation of, 270–272
- in the microenvironment, 272, 276–285
- migration and, 287–290
- production of, 273–275
- receptors, 115, 253–254, 285–287
- release/secretion issue, 252–253
- Lysophosphatidylcholine (LPC), 243, 244, 253, 274–275, 277
- Lysophospholipase A₁ (LPA₁), 253–254
- Lysophospholipase D (LysoPLD), see Autotaxin/lysophospholipase D (ATX/LysoPLD)

M

- Magnetic resonance imaging (MRI), 376, 377–378
- Malignant bowel obstruction (MBO), 55–56
- Mammalian target of rapamycin (mTOR), 72, 89, 113, 119, 365, 372
- Mammary gland cancer, 369, 370
- MAPK, see Mitogen-activated protein kinase (MAPK)
- Marimastat, 73
- Maspin, 135
- Matrigel invasion experiments, 279
- Matrix metalloproteinase (MMP)
 - lysophosphatidic acid and, 276, 278, 280–282, 284
 - membrane-type, 1, 280, 327, 329f
 - as a therapeutic target, 72–73
- Matrix metalloproteinase-1 (MMP-1), 277, 282
- Matrix metalloproteinase-2 (MMP-2), 345, 369
 - cell adhesion and, 307, 336,
 - EGFR and, 210, 212, 216
 - lysophosphatidic acid and, 280–281, 282
- Matrix metalloproteinase-3 (MMP-3), 216, 282

- Matrix metalloproteinase-7 (MMP-7), 277, 281–282, 299
- Matrix metalloproteinase-9 (MMP-9), 87, 327
cell adhesion and, 308
EGFR and, 208, 210, 212, 213, 216
lysophosphatidic acid and, 280, 282
- Matrix metalloproteinase-14 (MMP-14), 212
- Matuzumab, 68, 91
- Maximal surgical effort concept, 45–48
- MCAs, *see* Multicellular aggregates (MCAs)
- MCF-7 (cell line), 140
- MCJ, *see* Methylation controlled DNAJ (MCJ)
- MEK, 74, 274, 366
- MEKK1, 289–290
- Melanoma, 74, 78, 231, 233, 256, 275, 341
- Melphalan, 45
- Membrane-type 1 matrix metalloproteinase (MT1-MMP), 280, 327, 329f
- Mesenchymal stem cell migration, 288
- Mesothelin, 94
- Metastasis, 269–270, 335–347
2-D models of, 338–339
3-D metastasis models of, *see* Three-D organotypic metastasis models
EGFR and, 210
microenvironmental regulation of, 319–330
overview, 335–360
- Methylation controlled DNAJ (MCJ), 135, 137
- Mice, 190, 206, 307, 358, 359
angiopoietin and, 310
autotaxin and, 260, 273
genetically induced transformation in, 364–366
in vivo imaging of, 376–379
lysophosphatidic acid and, 270–271, 287, 288
metastasis in, 335, 336
P-selectin and, 304
sphingosine-1-phosphate and, 256, 258–259
spontaneous immortalization and transformation in, 360–361
TACE and, 283
viral immortalization and transformation in, 359
See also Genetically engineered mouse (GEM) models; Transgenic mouse models; Xenograft mouse models
- Microenvironment
of ascitic tumor cells, 322–324
cell adhesion and, 309–311
EGFR in, 210–213
lysophosphatidic acid in, 272, 276–285
metastasis regulated by, 319–330
of omental metastasis, 336–338, 343–344
pericellular adhesive, 320–322
of peritoneal metastasis, 327–329, 342
- MicroRNA (miRNA), 134, 136, 137, 170
- Microvessel density (MVD), 65
- MiR-140, 136, 137
- Mir-15/16, 134
- MIS, *see* Müllerian inhibiting substance (MIS)
- Mitogen-activated protein kinase (MAPK), 19, 21, 64, 67, 74, 75f
- MMAC-1, *see* Phosphate and tensin homologue (PTEN)
- MMP, *see* Matrix metalloproteinase (MMP)
- MNU, *see* *N*-Methyl-*N*-nitrosourea (MNU)
- Monoclonal antibodies, murine, 67–68
- Mortality rates, 3, 63, 85, 241, 320
- MOSE (cell line), 360, 361–362, 366
- MOVCAR (cell line), 368
- MRI, *see* Magnetic resonance imaging (MRI)
- MTA-1, 136
- mTOR, *see* Mammalian target of rapamycin (mTOR)
- MUC16, 368
- Mucinous ovarian cancer, 255, 259, 319, 353
- Müllerian inhibiting substance (MIS), 193, 367–369, 375
- Müllerian tumors, 319, 353, 358, 364
- Multicellular aggregates (MCAs), 320, 322, 324–325, 327, 330
- Myc, 134
- Myelodysplastic syndrome (MDS), 138
- N**
- N*-Acetylglucosamine 6-*O*-sulfotransferase2 (GlcNAc6ST-2), 304
- N*-cadherin, 292, 298
EGFR and, 214, 214–217
melanoma and, 341
metastasis and, 322, 325
- Neoadjuvant chemotherapy, 49–51
- N*-Ethylmaleimide, 255
- Neuregulin-1, 204
- Neuregulin-2, 204
- Neuregulin-3, 204
- Neuregulin-4, 204
- Neuroglycan C, 204
- NF1, 231

- NFAT1, 245
 NFAT5, 245
 NF- κ B, *see* Nuclear factor kappa B (NF- κ B)
 4-(*N*-Hydroxyphenyl) retanimide (4-HPR), 355
 NIH-3T3 (cell line), 275
 Nkx type transcription factors, 154
N-Methyl-*N*-nitrosourea (MNU), 358
 NOE 033 (cell line), 278
 NOE 035 (cell line), 278
 NOEY2, 96t
 Nonhomologous end-joining (NHEJ), 117
 Non-small cell lung cancer (NSCLC), 70, 74, 76, 208
 Nonsteroidal anti-inflammatory drugs (NSAIDs), 5, 19
 Novel therapeutics
 epigenetic, 139–140
 targets for, 65–78, 85–99
 See also Biomarker targets
 NP603, 311
 N-ras, 229, 231, 232
 Nuclear factor kappa B (NF- κ B), 92, 116
 chemoprevention and, 6, 8
 lysophosphatidic acid and, 277, 279, 290
 phytochemicals and, 21
 NuRD, 134, 136
 NuTu 19 (cell line), 361
 NY-ESO, 93
- O**
 OBCAM, *see* OPCML
 Omega-3 fatty acids, 22
 Omental biopsy, 36
 Omental metastasis, 336–338, 341–342, 345, 346, 347
 Oncogenic viruses, 359–360
 OPCML, 111t, 117, 122, 135
 Oral contraceptives, 4, 10–14, 173, 192, 354–355
 Organotypic models of metastasis, *see* Three-D organotypic metastasis models
 Ovarian Cancer Study Group, 39
 Ovarian surface epithelium, *ex vivo* transformation of, 358–359
 OVCA1 (gene), 96t, 111t, 120, 122
 OVCA3 (cell line), 243, 250
 OVCA420 (cell line), 243
 OVCA429 (cell line), 278, 284
 OVCA432 (cell line), 278
 OVCA433 (cell line), 214–215, 278
 OVCAR3 (cell line), 257, 272, 278, 285, 340
 Overall survival (OS), 47–48, 66, 181
 Ovulation, 4, 14, 192
- P**
 p16, 138
 p21, 92, 113, 232, 355
 p27, 113
 p38, 277, 280, 282
 p42, 280
 p44, 280
 p53, 87, 92, 109, 112, 135, 138, 232, 347, 363
 in animal models, 25, 355, 358, 364–366, 369, 370–371
 chemoprevention and, 6, 7–8
 conditional inactivation of, 370–371
 location and function of, 111t, 118–119
 omega-3 fatty acids and, 22
 PEG3 and, 121
 as a therapeutic target, 93–94, 95t
 UCN-01 and, 76
 p105, 196
 p110, 196
 PA, *see* Phosphatidic acid (PA)
 Paclitaxel (Taxol), 63, 71, 86, 135, 137, 209, 368, 377
 PAF AHase, *see* Platelet activating factor acetylhydrolase (PAF AHase)
 Pancreatic cancer, 74, 170, 231, 232, 370
 Panitumumab, 68
 Para-aortic lymphadenectomy, 36–38, 40
 Parathyroid hormone-related protein/peptide (PTHrP), 168, 172
 PARP, *see* Poly(ADP-ribose) polymerase (PARP) inhibitors
 Pathogenesis of ovarian cancer, 192–193
 Paullones, 76
 Paxillin, 288, 290, 291
 P-cadherin, 298, 302
 PD 161570, 311
 PD 184352, 74
 PD98059, 74, 366
 PDGFR, *see* Platelet-derived growth factor receptor (PDGFR)
 PEG3, 111t, 112, 121, 122, 135
 Pericellular adhesive microenvironment, 320–322
 Peritoneal metastasis, 337
 3-D metastasis models of, 341, 345–347
 cadherin expression and, 324–325
 integrin-matrix interaction in, 327–329
 microenvironment of, 325–327, 341–342

- Peritoneal washing, 36
- Peroxisome proliferator-activated receptor γ (PPAR γ), 254
- Pertuzumab, 68–69, 89, 90t
- PET, *see* Positron emission tomography (PET)
- Phosphate and tensin homologue (PTEN), 109, 122, 135, 136, 137, 347
in animal models, 371–374
chemoprevention and, 7
location and function of, 110t, 116–117
as a therapeutic target, 97t
- Phosphatidic acid (PA), 254, 255, 256
- Phosphatidic acid phosphatase type 2A (PPAP2A), 255
- Phosphatidylcholine (PC), 250
- Phosphatidylinositol 3'-kinase (PI3K), 88, 91, 116, 231, 280, 307, 372, 374
chemoprevention and, 6, 7
E-cadherin and, 325
mTOR and, 72
retinoids and, 19
- Phosphatidyl specific phospholipase A₁ (PS-PLA₁), 252
- Phospho-epidermal growth factor receptor (pEGFR), 208, 216
- Phospholipase A₁ (PLA₁), 273
- Phospholipase A₂ (PLA₂), 241, 247–252, 273
calcium-independent, 247, 249–252, 253, 260, 273, 273, 274
cytosolic, 247, 248–249, 252, 260, 273, 274, 275
secreted, 247, 249, 252–253, 273–274
- Phospholipase D (PLD), 252
- Phytochemicals, 21–22
- PI3K, *see* Phosphatidylinositol 3'-kinase (PI3K)
- PIGF (Placenta-derived growth factor), 64, 65
PIK3CA, 91, 96t
- Piwi-interacting RNAs (piRNAs), 134
- PLA, *see* Phospholipase A₁ (PLA₁);
Phospholipase A₂ (PLA₂)
- Placenta-derived growth factor-1 (PIGF-1), 64, 65
- Placenta-derived growth factor-2 (PIGF-2), 64, 65
- Plakoglobin, 299
- Plasminogen, 168
- Plasminogen activator inhibitor-1, 92
- Platelet activating factor acetylhydrolase (PAF AHase), 247
- Platelet-derived growth factor receptor (PDGFR), 66, 88, 310
- Platelet factor-4 (PF-4), 65
- Poly(ADP-ribose) polymerase (PARP) inhibitors, 77–78
- Polysulfates, 76
- Positron emission tomography (PET), 376, 377–378
- PP2A, 369
- PPAP, *see* Phosphatidic acid phosphatase type 2A (PPAP2A)
- PPAR γ , *see* Peroxisome proliferator-activated receptor γ (PPAR γ)
- Pregnancy, 4, 14, 192
- Prevalence of ovarian cancer, 63, 85
- Primates, non-human, 10–13, 354–355
- Proangiogenic factors, 276–278
- Procaine, 138
- p160ROCK, 233
- Progesterone, 173
- Progestins, 4–5, 10–14, 355
- Progression, 5
- Progression-free survival (PFS), 47–48, 66
- Promotion, 5
- Prostate cancer, 235
animal models of, 369
kallikreins and, 170, 172
lysophosphatidic acid and, 255
MMP-7 and, 281
omega-3 fatty acids and, 22
- Prostate specific antigen (PSA), *see* KLK3
- Prostatic acid phosphatase, 255
- Proteases, 278–284
- Proteinase-activated receptors (PARs), 169
- Protein kinase B, 115
- Protein kinase C, 89, 279–280
- PS-341, *see* Bortezomib
- P-selectin, 303, 304, 305
- P-selectin glycoprotein ligand-1 (PSGL-1), 305
- PSI-697, 305
- PTEN, *see* Phosphate and tensin homologue (PTEN)
- PTHrP, *see* Parathyroid hormone-related protein/peptide (PTHrP)
- PTK787, 66
- Purine derivatives, 76
- Pw1, *see* PEG3
- PXD101, 139
- R**
- R182 (cell line), 282
- R306465, 139
- Rab, 229, 233–235

- Rabbits, 359, 362
 Rac1, 232
 Rac1b, 216
 Rac2, 232
 RAD001, *see* Everolimus (RAD001)
 Raf, 67, 310
 Raf-1, 279
 Ran, 229
 Rap, 112
 Rapamycin, 72, 366
 See also Mammalian target of rapamycin (mTOR)
 Ras, 25, 67, 92, 112, 113–114, 117, 134, 275, 279, 307
 lysophosphatidic acid and, 286, 290
 subfamily of GTPases, 229, 231–232
 superfamily of GTPases, 229–236
 Ras/raf pathway, 71, 88
 RASSF1A, 110t, 113–114, 122, 135, 137
 Rats, 190, 209, 233, 358, 359, 360–361, 363
 Rb, 76, 112, 135, 355, 369, 370–371
 RCAS retroviral vectors, 364, 366
 Receptor tyrosine kinases (RTKs), 64
 Recurrent ovarian cancer
 cytoreduction for, 51–54
 molecularly targeted agents for, 88–93
 Red wine, 20–21
 Regulator of G-protein-signaling (RGS)
 proteins, 288–289
 Remodeling and spacing factor (RSF), 136
 Renal-cell carcinoma, 73, 275
 Resveratrol, 8, 9, 20–21
 Retinoids, 4, 5, 11, 19–20
 RGS proteins, *see* Regulator of G-protein-signaling (RGS)proteins
 Rho
 lysophosphatidic acid and, 281, 287–288, 289, 291
 subfamily of GTPases, 229, 232–233
 RhoA, 232, 233, 281, 288, 307
 RhoC, 232, 233
 RMG-1 (cell line), 357
 RNA-induced silencing complex (RISC), 132f, 134
 RNA polymerase, 132f
 ROCK, 233, 281, 288
 ROSE (cell line), 359, 360–361, 363
 RPS6KA2, 110t, 116, 122

S
 SIP, *see* Sphingosine-1-phosphate (SIP)
 S6, 372

 S-110, 138
 SAHA, 139
 SB202190, 280
 SCH115777, 235
 SCH66336, 71
 Scriptaid, 139
 Secreted phospholipase A₂ (sPLA₂), 247, 249, 252, 253, 273–274
 Secreted protein acidic and rich in cysteine, *see* SPARC
 sEGFR, *see* Soluble epidermal growth factor receptor (sEGFR)
 Selectins, 302–305
 angiogenesis and, 305
 endothelium (E), 303, 304, 305
 lymphocyte (L), 303
 platelet (P), 301, 304, 305
 Selective estrogen receptor modulators (SERMS), 355
 Semenogelin I, 168
 Semenogelin II, 168
 Serous ovarian cancer, 259, 319, 353, 358
 SF-1126, 91
 SH3, 67
 SHIN-3 (cell line), 117
 Sialyl-Lewis^a (sLe^a), 303, 304
 Sialyl-Lewis^x (sLe^x), 303, 304
 Siglec gene family, 165
 14-3-3 Sigma, 137, 139
 Simian virus 40 T-antigen, *see* SV-40 T-antigen
 Single hit hypothesis, 111
 Single photon emission computed tomography (SPECT), 376
 SiRNA, 156, 206, 211, 213
 Sirolimus, *see* Rapamycin
 SKOV3 (cell line), 72, 115, 139, 152, 233, 243, 244, 250, 251, 252
 autotaxin and, 273
 lysophosphatidic acid and, 273, 274, 275, 284, 287, 292
 sphingosine-1-phosphate and, 257
 urokinase plasminogen activator and, 276, 279
 VEGF and, 275
 Small interfering RNA (siRNA), 256, 279, 282, 283, 284, 286, 328
 Small-molecule tyrosine kinase inhibitors (TKIs), 69
 Snail, 213
 SNCG, 135

- Soluble epidermal growth factor receptor (sEGFR), 189–198, 207
 in differential diagnosis, 196–197
 isoforms of, 189–191
 laboratory findings on, 194–196
 pathogenesis and, 192–193
 treatment and outcome, 197–198
- Sorafenib, 68, 73, 90, 310
- Soy, 7, 21–22
- SPARC, 96t, 110t, 114–115, 122, 308
- SPC, *see* Sphingosylphosphorylcholine (SPC)
- Sphingosine-1-phosphate (S1P), 241, 243, 244–245, 253, 254, 256–259, 277, 286, 292
 in cells, 256
 metabolism of, 258–259
 multifaceted effects of, 257–258
 in ovarian cells, 256–257
- Sphingosylphosphorylcholine (SPC), 243, 277
- SPLA₂, *see* Secreted phospholipase A₂ (sPLA₂)
- Src, 91, 289, 307, 327, 362, 368
- Src2, 67
- Stage I cancer, 39, 40, 194, 195, 211, 322
- Stage II cancer, 39, 199, 211, 270, 323
- Stage III cancer, 39, 40, 63, 193, 194, 197, 211, 323
 cytoreduction and, 47, 48
 lysophosphatidic acid and, 269, 270, 271
- Stage IV cancer, 96, 193, 194, 195, 197, 211, 323
 cytoreduction and, 47, 48–49
 lysophosphatidic acid and, 269, 270
- Staging, 35–56
 of advanced-stage ovarian cancer, 44–56
 of early-stage ovarian cancer, 35–44
 system for, 35–40
- STAT3, 113, 368
- Statins, 235
- Staurosporins, 76
- Stem cells, cancer, 158–160
- STI571, *see* Imatinib
- STK17A, 122
- Stomach cancer, 191, 281
- SU1498, 276, 280
- SU5416, 363
- Suberoylanilide hydroxamic acid, 139
- Sunitinib, 66, 88
- Suppressor of Zeste-12 (SUZ12), 132f
- Surgery, 35–56
 for advanced-stage ovarian cancer, 44–56
 for early-stage ovarian cancer, 35–44
 fertility preservation and, 40–44
 for malignant bowel obstruction, 55–56
- Survival rates, 63, 85, 193–194, 306, 325
 actinin-4 and, 308
 cisplatin and, 86
 cytoreduction and, 46, 47–48, 53
 disease-free, 181
 EGFR and, 207–208
 kallikreins and, 181
 overall, 47–48, 66, 181
 progression-free, 47–48, 66
- SV-40 T-antigen, 152, 208, 278, 359, 360, 363–364, 368
- Swedish Mammography Cohort, 21
- SWI/SNF, 134, 136
- Symptoms of ovarian cancer, 193–194
- Systematic peritoneal surface biopsy, 36
- T**
- TACE, *see* Tumor necrosis factor- α converting enzyme (TACE)
- TAM67, 9
- Tamoxifen, 11
- Taxol, *see* Paclitaxel (Taxol)
- TBC1269, 305
- Temsirolimus, 72, 89
- Testicular cancer, 170, 233
- Testosterone, 358
- TGF, 11–14, 290, 329, 355
See also specific Transforming growth factor
- Thioether amide-PC (TA-PC), 247
- Three-D organotypic metastasis models, 335–348
 advantages of, 346
 designing, 341–346
 2-D models compared with, 338
 rationale for, 341
- Thrombospondin (TSP), 65, 87
- Thyroid cancer, 235, 245
- Tissue inhibitors of metalloproteinase (TIMPs), 280, 282–283
- TMS1/ASC, 135
- TNF, *see* Tumor necrosis factor- α (TNF- α)
- Tomoregulin, 204
- Topoisomerase II, 213
- Topotecan, 79
- Total abdominal hysterectomy (TAH), 36, 38, 40
- Toyocamycin, 76
- TP53, 93
- TRAG-3, 135

- Transforming growth factor- α (TGF- α), 193, 203, 206, 213
- Transforming growth factor- β (TGF- β), 290, 355
 autotaxin and, 245
 KLK3 and, 168
 omega-3 fatty acids and, 22
 progestins and, 11–13
 retinoids and, 19, 20
 vitamin D and, 14, 17, 18
- Transforming growth factor- β 1 (TGF- β 1), 11–14
- Transforming growth factor- β 2 (TGF- β 2), 11–14, 329
- Transforming growth factor- β 3 (TGF- β 3), 11–14
- Transgenic mouse models, 232
 development of, 367–369
 urokinase plasminogen activator and, 278–279
- Trastuzumab, 67–68, 89
- Trichostatin A, 155
- Triphasil, 10–13
- Trocar site, 36–37
- TSP, *see* Thrombospondin (TSP)
- Tuberous sclerosis complex (TSC), 72
- Tubulin, 138
- Tumor necrosis factor- α converting enzyme (TACE), 283
- Tumor necrosis factor- α (TNF- α), 281, 324
- Tumor suppressor genes, 87, 109–122
 descriptions of, 112–121
 list of, 110–111t
- Turmeric, 7
- TVA, 364–365, 366
- Twin pregnancy, 14
- Two-D metastasis models, 338
- Two-hit hypothesis, 111–112
- Type I malignancies, 319–320, 347
- Type II malignancies, 319–320, 347
- Tyrosine kinase (TK) type 1, 88
- U**
- UCN-01, 76–77
- Ultrasound (US), 376, 377–378
- Urokinase plasminogen activator (uPA)
 kallikreins and, 172
 lysophosphatidic acid and, 274–276, 283, 286
 as a therapeutic target, 92, 96t
- Uterine cancer, 233
- V**
- Valatanib, 66
- Valproate (VPA), 139, 140
- Vandetanib, 70
- Vascular endothelial growth factor-164 (VEGF-164), 362
- Vascular endothelial growth factor-165 (VEGF-165), 363
- Vascular endothelial growth factor-B (VEGF-B), 64, 66
- Vascular endothelial growth factor-C (VEGF-C), 64
- Vascular endothelial growth factor-D (VEGF-D), 64
- Vascular endothelial growth factor-E (VEGF-E), 64
- Vascular endothelial growth factor receptor (VEGFR), 64, 91, 276–277, 309–310
- Vascular endothelial growth factor receptor-1 (VEGFR-1), 64, 244, 286, 309
- Vascular endothelial growth factor receptor-2 (VEGFR-2), 64, 244, 275, 277, 280, 286, 309, 310
- Vascular endothelial growth factor receptor-3 (VEGFR-3), 64
- Vascular endothelial growth factor (VEGF), 8, 320
 in animal models, 368, 369
 ARHI and, 113
 autotaxin and, 243, 245, 273
 cell adhesion and, 306, 309
 lysophosphatidic acid and, 275–276, 280, 281, 282, 284, 286
 PTEN and, 117
 SPARC and, 115
 sphingosine-1-phosphate and, 256
 as a therapeutic target, 64–66, 87, 88, 89, 90t, 92
- Vascular endothelial growth factor-A (VEGF-A), 65, 66, 244
- Vascular endothelial growth factor-Trap (VEGF-Trap), 66
- Vatalanib, 98
- VATS, *see* Video-assisted thorascopic surgery (VATS)
- VE-cadherin, 298
- VEGF, *see* Vascular endothelial growth factor (VEGF)
- VEGFR, *see* Vascular endothelial growth factor receptor (VEGFR)
- Vidaza, 138, 140

Video-assisted thoroscopic surgery (VATS),
44, 48–49
Vimentin, 210, 214, 215–216, 325
Vitamin A, 6
Vitamin D, 4, 5, 11, 14–19
Vitamin E, 6
Vitronectin, 308, 337, 345
Vorinostat, 139
VPC23019, 257

W

Wilms tumor, 235
Wilms tumor gene product 1 (WT1), 328
Wine, red, 20–21
World Health Organization (WHO), 13
Wortmannin, 280
WWOX, 111t, 118, 122

X

Xenograft mouse models, 72, 117, 235,
355–357
AZD6244 and, 74

chemoprevention in, 23–24
EGFR in, 206, 209, 212
intraperitoneal implantation,
355, 356
lysophosphatidic acid acyltransferase
and, 255
metastasis in, 335
orthotopic implantation, 355, 356–357
subcutaneous implantation, 355
X-linked nonspecific mental
retardation, 234

Y

Y-27632, 287–288

Z

ZAC1, *see* LOT-1
ZD1839, *see* Gefitinib
ZD4054, 212
ZD6474, 68t, 70
Zebularine, 138, 139–140
Zolinza, 139